ImmuPharma PLC is stepping up efforts to secure a licensing deal for its P140 autoimmune platform, with discussions underway with multiple potential partners under confidentiality agreements.
The company recently showcased the programme at the Bio-Europe Spring conference in Lisbon, where management held a series of meetings aimed at advancing partnering opportunities. P140 is described as a core value driver for the business.
Supporting this push, ImmuPharma has made progress on both the scientific and intellectual property fronts. It has received a positive initial examination report from the UK Intellectual Property Office for its P140 patent application, with plans to expand protection globally via a Patent Cooperation Treaty (PCT) filing.
At the same time, a new study designed to strengthen the diagnostic component of P140 has delivered positive results, improving the statistical robustness of the dataset. A manuscript is now being prepared for submission to a peer-reviewed journal, which the company intends to use to further validate the programme within the scientific community.
ImmuPharma believes these developments enhance both the commercial attractiveness and scientific credibility of P140, as it targets a value-accretive deal in 2026.
Dr Sébastien Goudreau, Chief Scientific Officer of ImmuPharma PLC, said:
“The receipt of the first Combined Search and Examination Report for our UK P140 patent application, together with the new supporting study results, represents an important step in strengthening the scientific and intellectual property foundation of the program. In parallel, the scientific manuscript now in preparation will help the broader scientific community to understand the unique mechanism of P140 as a precision therapy for patients with Type M immune disorder. This work reinforces our confidence in P140’s potential to become a first‑in‑class, disease‑modifying approach across multiple autoimmune diseases.”
